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Immunoglobulin idiotypes (Id) 1 have been studied extensively since they were 
first recognized by Kunkel et al.  (1) and by Oudin and Michel (2) in  1963.  Id, 
along with  homologous anti-Id  antibodies,  are thought  to be components of a 
network  of complex  reactions  that  regulates  a  given  immune  response.  Such 
regulation at the level of Id recognition was postulated by Jerne (3) to involve a 
series of Id-anti-Id reactions that are able to control immune responses at both 
the afferent and efferent modes. Numerous studies have implicated Id networks 
in regulating the immune response to a  large variety of haptens and protein or 
carbohydrate antigens  (reviewed in 4 and  5).  Recently, anti-Id antibodies have 
been used to enhance the murine antibody response to transplantation  antigens 
(6,  7) and  to induce protective immunity  in  mice against  lethal  infection  with 
trypanosomiasis (8). 
Hepatitis B surface antigen (HBsAg), the envelope material of hepatitis B virus 
(HBV), is produced in an overwhelming excess by infected hepatocytes during 
the course of an H BV infection (9, 10). The presence of HBsAg is often associated 
with the development of chronic liver disease and primary carcinoma of the liver 
(1 1). Previous studies from this laboratory (12-15) have characterized a common 
Id shared by human antibodies to HBsAg (anti-HBs). This common Id was also 
detected on anti-HBs produced in BALB/c mice and six other species, indicating 
that an interspecies idiotypic cross-reaction was expressed (16). The involvement 
of an Id-anti-Id network was indicated in that the numbers of anti-HBs plaque- 
forming  units  (PFU) in  the  spleens of BALB/c mice  were enhanced  by prior 
injection of anti-Id antibodies (17). 
In  this  report,  we  explore  the  effects of in  vivo administration  of anti-Id 
antibodies on the humoral  murine anti-HBs response.  The serologic character- 
istics of the anti-Id-induced  anti-HBs molecules were examined for expression 
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of the interspecies Id markers. The implications of these observations with regard 
to Id networks and HBV infections are discussed. 
Materials and Methods 
Preparation  and  Put,cation  of Anti-Id  Antibodies.  The  preparation  of rabbit anti-Id 
antiserum and  its specificity have been described  in detail  elsewhere (12,  13).  Anti-Id 
antisera  were  affinity  purified  by  acid  elution  from  Id-containing  immunoadsorbent 
columns by methods similar to those reported elsewhere (18).  Concentrations of anti-Id 
antibodies were determined spectrophotometrically using an extinction coefficient of 15 
for a  1% solution at 280 nm. 
Determination  of Anti-HBs  Activity.  The anti-HBs activity  in  the  mouse  antisera  was 
determined by a solid-phase radioimmunoassay (RIA) referred to as micro-SPRIA (19). 
Briefly, 200 ng of HBsAg, subtype adw, was coated onto the wells of a microtiter plate. 
Fivefold dilutions of mouse antisera were added to the wells after postcoating and washing 
steps. The unbound  serum protein  was washed off and  ~SI-labeled goat anti-mouse 7 
chain-specific antiserum (Kirkegaard and  Perry  Laboratories,  Inc., Gaithersburg,  MD) 
was added.  Residual radioactivity was removed and the wells were washed and counted. 
The anti-HBs endpoint titers were determined as the dilution of mouse antisera that gave 
an arbitrary positive (S) to negative (N) cpm ratio of 2.1  (19).  IgM anti-HBs was similarly 
detected  using  a  radiolabeled  rabbit  anti-mouse  #  chain-specific  antiserum  that  was 
generated in this laboratory. This reagent was prepared by adsorption of a rabbit anti- 
mouse monoclonal IgM antiserum over an immunoadsorbent column containing mouse 
IgG to remove anti-light chain and anti-heavy chain isotype activities. The immunization 
protocols to produce the reagent and the preparation of immunoadsorbent columns have 
been described in detail elsewhere (18,  20).  In addition, 200 ng of HBsAg, subtypes ayw 
and adr, were coated on the wells of a microtiter plate, and a micro-SPRIA was similarly 
performed to ascertain the subtype specificity of the mouse anti-HBs. A commercial solid- 
phase RIA kit was also used for quantification ofanti-HBs (AUSAB; Abbott Laboratories, 
North Chicago, IL). 
Expression of the Interspecies Id on Anti-HBs.  The detection  of the  interspecies  Id on 
mouse anti-HBs has been described previously (16).  Briefly, a limiting dilution of rabbit 
anti-Id antisera was coated onto the wells of microtiter plates, and the ability of mouse 
antisera to block the binding of ~SI-labeled Id determined. The percentage inhibition of 
binding was calculated as previously described (12). 
Isolation and Purification of  HBsAg.  The purification of22-nm HBsAg particles, subtypes 
adw, ayw, and adr, was performed by the method described elsewhere (21). Human plasma 
positive for the three HBsAg subtypes were kindly provided by Dr. H. Fields, Centers for 
Disease Control,  Atlanta,  GA.  The concentration  of HBsAg was determined  using an 
extinction coefficient of 37.26 for a  1% preparation at 280 nm. 
In Vivo Administration  of Anti-ld Antibodies.  Adult female BALB/c mice (Charles River 
Breeding Laboratories, Wilmington, MA) were given intraperitoneal injections of affinity- 
purified anti-Id antibodies either in saline or as an alum precipitate at pH 7.0 (22). Control 
antibodies  were  IgG preparations  from  normal  serum  obtained  from  rabbits  before 
injection  of the  Id  (pre-IgG).  These  antibodies  were  also  given  in  soluble  or  alum- 
precipitated  forms,  and  the  concentration  of IgG was  similarly determined  using  an 
extinction coefficient of 15. Groups of mice received either anti-Id or pre-IgG before an 
intraperitoneal  injection  of 6  #g of HBsAg in  saline.  Mice  were  bled  12  d  after the 
injection of HBsAg. Serum obtained from each mouse before any immunization served 
as a  negative control  for each animal.  Based on the  level of anti-HBs activity of each 
group  of mice,  the  optimal  dose  of anti-Id antibodies  and  the  optimal  time interval 
between injections of anti-Id and HBsAg were established. These parameters were then 
used to induce anti-HBs activity by the injection of anti-Id antibodies alone. 
Iodination.  50 t~g each of goat anti-mouse ~, chain, rabbit anti-mouse t~ chain, and the 
anti-HBs Id preparations were labeled with Nal25I (Amersham Corp., Arlington Heights, 
p  "  12~  IL) using the chloramine-T reaction (23).  rotein-assoclated and free  I were separated KENNEDY  AND  DREESMAN  657 
on  PD-10  columns (Pharmacia  Fine Chemicals,  Piscataway,  NJ).  More than  95%  of the 
radioactivity  of the  labeled  preparations  was  precipitable  with  a  final  concentration  of 
10% trichioroacetic acid. 
Statistical Methods.  The  levels of significance (P values) were obtained  using the two- 
tailed Student's t test (24) on the Iog~0 of the reciprocal arithmetic mean anti-HBs titer of 
each group of mice. 
Results and Discussion 
In a  recent  study  (17),  we  reported that  in  vivo administration of anti-Id 
antibodies before the injection of HBsAg increased the number of anti-HBs PFU 
in the spleens of BALB/c mice when compared with mice injected with control 
pre-IgG  before  HBsAg  stimulation (17).  In  addition,  mice  receiving anti-Id 
antibodies  alone  had  a  significantly  higher  number  of anti-HBs  PFU  when 
compared with mice treated with only control antibodies. These data suggested 
that the immune response to HBsAg may be regulated via Id-anti-Id interactions. 
In this ~'eport,  the presence of anti-Id-induced anti-HBs activity in serum of 
BALB/c mice was investigated to ascertain whether these antibodies expressed 
an interspecies Id that would be indicative of an Id-anti-Id-controlled network. 
The first experiment was performed to  determine the  most  immunogenic 
form(s) of anti-Id antibodies for enhancing the anti-HBs response. Our previous 
study used soluble anti-Id antibodies in the modulation of the murine anti-HBs 
response at the spleen cell level; however, other investigators demonstrated that 
high levels of antibody could be  induced in their  Id systems without antigen 
stimulation, by injecting cross-linked anti-Id (25,  26).  Because higher titers of 
anti-HBs were generated in experimental animals when HBsAg was alum-precip- 
itated rather than in aqueous solution (22), we decided to compare the effects 
on the anti-HBs response by injecting alum-precipitated material vs. soluble anti- 
Id antibodies before HBsAg stimulation. As shown in Table I, the mean anti- 
HBs titer was higher in groups of mice receiving alum-precipitated anti-Id when 
compared with anti-Id in saline before HBsAg injection (AUSAB titers of 487.5 
TABLE  I 
Comparison of Alum-precipitated and Soluble Anti-Id for Induction of Anti-HBs* 
Second in- 
First injection  jection 
No. of  Anti-HBs response 
mice  (mean _+ SEM)* 
Micro-SPRIA 
Anti-HBs  Anti-HBs 
IgGQ  IgM  m 
Anti-Id alum-precipitated  HBsAg  4  487.5 _  315.0  4,938  1,250 
Anti-ld soluble  HBsAg  4  72.5 "4- 50.0  86  1,000 
Pre-rabbit IgG alum-we-  HBsAg  4  <5.01  <5.0  <5.0 
cipitated 
Pre-rabbit IgG soluble  HBsAg  4  6.25 +  1.08  30  50 
* Each group of mice received 40 ~tg of anti-Id or pre-IgG on day 0, followed by 6 pg of HBsAg on 
day 14, all by the intraperitoneal route. Mice were bled on day 26. 
* The values are the reciprocal dilution of antisera that gave an endpoint S/N of 2.1  (see Materials 
and Methods) as measured by AUSAB. 
g The mean value of reciprocal dilution of antisera that gave an endpoint S/N of 2.1  as measured 
by SPRIA using J2~I-labeled goat anti-mouse 3' chain-specific antiserum. 
! The mean value of reciprocal dilution of antisera that gave an endpoint S/N of 2.1  as measured 
by SPRIA using ~SI-labeled rabbit anti-mouse u chain-specific antiserum. 
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vs. 72.5). Only one of four mice produced a detectable anti-HBs response in the 
soluble control pre-IgG group, whereas no mice receiving alum-precipitated pre- 
IgG  before  HBsAg produced  a  detectable anti-HBs  response  at  a  1:5  serum 
dilution  (Table  I).  In this experiment,  the anti-HBs response was measured by 
both a  commercial  RIA that  detects  IgM and  IgG anti-HBs and  a  solid-phase 
RIA. For the remaining experiments, the solid-phase RIA was used for titration 
of the  mouse antisera  because  this  test  is  more  sensitive,  less expensive,  and 
requires  lower  quantities  of serum  (50  vs.  200  /~1) when  compared  with  the 
AUSAB (19). It was noteworthy that primarily IgM anti-HBs was detected by an 
IgM  type-specific RIA  in  the  group  of mice  injected  with  the  soluble anti-Id 
preparation. This was similar to our previous observations (17) where the number 
of direct IgM anti-HBs PFU was enhanced by prior injection of soluble anti-Id. 
In the second set of experiments, the optimal time interval between a primary 
injection of alum-precipitated  anti-Id antibodies and a subsequent HBsAg inoc- 
ulum for enhancing the anti-HBs response was determined.  Only IgG anti-HBs 
was measured since alum-precipitated anti-Id generated a potent secondary IgG 
response to HBsAg. In the previous experiment, the alum-precipitated anti-Id- 
treated  mice  generated  a  fourfold higher  IgG  anti-HBs titer  when  compared 
with  IgM  (Table I).  Also, previous observations in  reference to the  secondary 
humoral  anti-HBs response  indicated  that  IgG was the  predominant  antibody 
class present between  10 and  20 d  after HBsAg boost (27).  For these reasons, 
serum was routinely obtained 12 d after HBsAg injection and only IgG anti-HBs 
was assayed in the remainder of the study. Based on the data presented in Table 
II,  the optimal anti-HBs response occurred when  HBsAg was given  14 d  after 
priming  with  anti-Id.  In  each  instance,  groups  of mice  that  received  anti-Id 
antibodies before HBsAg generated a higher anti-HBs response when compared 
with the mice given pre-IgG.  The extremely high  standard  errors of the mean 
shown  in  Table  II  resulted  from  both  the  small  sample  size  (n  =  4)  and  the 
individual variations in anti-HBs titers among mice. 
The  optimal  quantity  of anti-Id  required  for enhancement  of the  anti-HBs 
response was determined  in  the next experiment  (Table III).  Previous reports 
(28, 29, reviewed in 30) have indicated that the concentration ofanti-Id antibod- 
ies was important in modulating the immune response to various antigens. Based 
on the two-tailed Student's t test, the greatest significant difference (P <  0.001) 
of the anti-HBs titer was noted in that group of mice inoculated with  50 #g of 
alum-precipitated  anti-Id  vs.  pre-IgG  before  HBsAg  stimulation.  Significant 
differences were also obtained in the groups of mice injected with 5 and 200 ~g 
of anti-Id  when compared with control groups inoculated with similar doses of 
pre-IgG. Although the mean anti-HBs titer was higher in the group treated with 
50 #g of anti-Id when compared with the groups given 5 or 200 t~g of anti-Id, 
the difference was not statistically significant.  The reasons for this higher mean 
anti-HBs titer again  may have reflected the  small  sample size (n  =  4) and  the 
individual variation of mice. No significant difference was noted in the anti-HBs 
response between the groups of mice receiving 500 ng of either anti-Id or pre- 
IgG before HBsAg (P >  0.2).  Also, the  mean  anti-HBs titer  was lower when 
compared  with  groups  of mice  receiving  higher  quantities  of anti-Id.  These 
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TABLE  II 
Optimal Time Interval Between Injection of Anti-ld and HBsAg for 
Induction of Anti-HBs* 
659 
HBsAg injec- 
tion (No. of  Anti-HBs response  s (mean + 
First injection  days after pri- 
mary inocula-  SEM) 
tion) 
Anti-Id 
Pre-IgG 
7  130 :t: 32.1 
14  4,222 __. 1,825.7 
21  200 "4" 64.6 
7  5+5.0 
14  <5.0  ~ 
21  30+  11.5 
* Each group of four mice received 40 #g of alum-precipitated anti-Id or 
pre-IgG on day 0, followed by 6 ug of HBsAg on the days specified, all 
by the intraperitoneal route.  Mice were bled  12 d  after injection with 
HBsAg. 
* The values are the reciprocal dilution of antiserum that gave an endpoint 
S/N of 2.1  (see Materials and Methods) as measured by the IgG anti- 
HBs SPRIA. 
All mice were negative for anti-HBs at a serum dilution of 1:5. 
TABLE  III 
Effect of Dose of alum-precipitated Anti-ld for Induction of lgG Anti-HBs  Using 
Micro-SPRIA * 
Logt0 of 
First injection  Second injec-  Reciprocal  the recip- 
tion  arithmetic  rocal arith-  Standard deviation  s 
mean titer  metic mean 
titer 
500 ng anti-ld  0  HBsAg  583  2.76  0.77 (p >  0.2)  I 
500 ng pre-IgG  HBsAg  86  1.93  0.26 
5 #g anti-Id  HBsAg  4,938  3.69  0.32 (p <  0.02) 
5 #g pre-IgG  HBsAg  66  1.82  0.88 
50 #g anti-Id  HBsAg  9,378  3.97  0.10 (p <  0.001) 
50 #g pre-IgG  HBsAg  6  0.78  0.18 
200 #g anti-ld  HBsAg  4,344  3.64  0.62 (p <  0.01) 
200 ttg pre-lgG  HBsAg  30  1.48  0.25 
* Each group of four mice received various concentrations of alum-precipitated anti- 
bodies on day 0, followed by 6 #g of HBsAg on day 14. Mice were bled on day 26. 
s The standard deviation of the log~0 of the reciprocal arithmetic mean titer. 
Q  Several of the mouse antisera were negative at the dilution tested. To facilitate the 
computations, the reciprocal of the titer was considered 0.5, assuming that greater 
than twofold concentration of the sample would give a positive result. 
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amounts of anti-Id antibodies failed to modulate the immune response (28, 29). 
Due to the heterogeneity of the variances among the groups receiving different 
antibody concentrations before antigenic stimulation,  the reciprocal arithmetic 
mean anti-HBs titers were expressed as values to iog~0 to facilitate the use of the 
parametric Student's t test rather than a nonparametric test (i.e., Kruskal-Wallis) 
for the  calculations  of significance  (17).  It  is  noteworthy that  some  mice that 
received pre-IgG before HBsAg produced an IgG anti-HBs response (Table III). 
The  reasons  for  such  a  response  are  not  known.  However,  it  was  consistent 
throughout the different experiments among the individual groups treated with 
pre-IgG. Based on the data presented in Table III, 50 ~g of anti-ld was selected 
as the optimal dose for generating anti-HBs in further experiments. 
Previously (17) we demonstrated that BALB/c mice receiving anti-Id antibod- 
ies alone generated indirect IgG anti-HBs PFU. These data indicated that anti- 
Id  antibodies  could induce  an  anti-HBs  response  without  HBsAg  stimulation. 
Similar results (6,  25,  reviewed in  30) have been reported in other Id systems 
where  administration  of anti-Id  without  antigen  exposure produced  idiotype- 
bearing molecules with antigen-binding activity. Based on the information estab- 
lished from the above experiments (Tables I-III), we attempted to induce anti- 
HBs  in  the  serum  of BALB/c  mice  by  injecting  anti-Id  alone.  A  statistically 
significant IgG anti-HBs response was generated in mice receiving two injections 
of 50  fzg of alum-precipitated  anti-Id  when  compared with  mice given  similar 
injections of pre-IgG (P <  0.001) (Table IV). A  mean anti-HBs titer of 1:1,000 
was  obtained  with  four  mice  receiving  anti-Id.  Conversely,  no  anti-HBs  was 
detected  in  four  mice  injected  with  control  pre-IgG  at  a  1:5  serum  dilution. 
These data indicate that anti-Id alone can produce detectable humorai anti-HBs 
in  BALB/c  mice.  Analysis  of the  anti-Id-induced  anti-HBs  demonstrated  the 
expression of the interspecies Id (Table IV). In this regard, four sera containing 
anti-HBs generated by anti-Id  induction inhibited the Id-anti-Id reaction from 
38  to  54%,  whereas  <10%  inhibition  was  obtained  with  the  non-anti-HBs- 
TABLE  IV 
Induction  of lgG Anti-HBs Antibodies that Express the Idiotype by Injection of Anti-ld* 
Logl0 of  Percent inhi- 
First injec-  Second injec-  Reciprocal  the recip-  bition of 
tion  tion  arithmetic  rocal  Standard deviation*  binding of 
mean titer  arithmetic  the Id-anti-Id 
mean titer  reactions  j 
Anti-Id  Anti-Id  1,000  3.0  0.24  (p <  0.001) I  38-54 I 
Pre-IgG**  Pre-IgG  <5  0.3  0.00  0-9 
* Each group of four mice received two injections of either 50 eg of alum-precipitated anti-ld or 
pre-IgG antibodies, 14 d apart. Mice were bled 12 d after the second injection. 
* The standard  deviation of the Iogt0 of the reciprocal arithmetic mean titer.  Four mice were 
injected in each group. 
f All sera were tested for the ability to inhibit the Id-anti-Id reaction at a 1:I0 dilution (16). 
! The range of mean values obtained from triplicate samples. 
I Determined by the two-tailed Student's t test. 
** All four mouse antisera were negative at the dilution tested. To facilitate the computations, the 
reciprocal of the titer was considered to he 0.5, assuming that greater than twofold concentration 
of the sample would give  a positive result. KENNEDY  AND  DREESMAN  661 
containing sera from the four mice injected with pre-IgG. In addition, all four 
preimmune sera  from  the  mice  that  produced anti-HBs  by  anti-Id  injection 
inhibited the binding of the Id to its anti-Id antiserum by <10%  (unpublished 
data). Together, these data indicate that in vivo administration of anti-Id anti- 
bodies in BALB/c mice induced anti-HBs that expressed a  similar interspecies 
Id. This interspecies Id was also detected in anti-HBs-positive mice that received 
either anti-Id or pre-IgG before HBsAg (Table V). 
It was of interest that anti-HBs from the four mice receiving anti-Id before 
HBsAg inhibited  the  Id-anti-Id reaction to  a  greater degree (32-61%)  when 
compared with anti-HBs from two of the four mice given pre-IgG before HBsAg. 
Although this greater amount of inhibition of the Id-anti-Id reaction may have 
reflected higher concentrations of anti-HBs  in  the mice treated with  anti-Id, 
previous studies indicated that  the level of interspecies Id inhibition  was not 
related to the anti-HBs titer (16).  The two mice that received pre-IgG before 
HBsAg and failed to produce a  detectable anti-HBs response inhibited the Id- 
anti-Id reaction by <5%. 
Serologically, HBsAg contains a  group-common antigenic reactivity referred 
to as the a determinant and two sets of allelic subtype determinants d or y and w 
or r (30, 31). In this regard, four possible HBsAg subtypes have been recognized: 
adw, ayw, adr, and ayr. The antibody specificity of the anti-Id-induced anti-HBs 
response  by which HBsAg determinants were recognized was  determined by 
RIA using microtiter plates coated with HBsAg subtypes adw, ayw, and adr. Each 
of the  four anti-Id-induced anti-HBs  bound  equally well  the  three different 
HBsAg subtypes (Table VI), indicating that the reactivities of the anti-Id-induced 
anti-HBs  were directed to the a  determinant. This  substantiates our previous 
observation (13) in that the binding of anti-Id antibodies was equally inhibited 
by  preincubating  the  anti-HBs  Id  with  three  of the  four  HBsAg  subtypes, 
indicating that the a  determinant was responsible for the induction of the Id. 
TABLE  V 
Expression of the Interspecies Idiotype in Mouse Anti-HBs* 
First injection  Second injection  Anti-HBs titer* 
Percent inhi- 
bition of the 
Id-anti-Id re- 
action 
Anti-Id  HBsAg  6,250  52 
250  32 
6,250  61 
6,250  60 
Pre-IgG  HBsAg  250  28 
>5  2 
>5  5 
25  19 
* Mice received either 5  t~g of alum-precipitated anti-Id or pre-IgG on 
day 0, followed by 6  #g of HBsAg on day  14.  Mice were bled on day 
26. 
* Reciprocal dilution of antisera that gave a  positive (S) to negative (N) 
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TABLE  VI 
HBsAg Spec~city of the Anti-Id-Induced Anti-HBs 
Reciprocal  S/N ratio* 
First in-  Second injec-  dilution of 
jection  tion  antisera  adw  ayw  adr 
tested 
Anti-Id  Anti-Id  50  8.3  7.8  7.7 
1,250  1.8  1.5  1.6 
Anti-ld  Anti-Id  50  8.0  7.8  7.8 
1,250  2.6  2.3  2.0 
Anti-ld  Anti-ld  50  7.9  8.4  7.7 
1,250  3.6  3.3  4.4 
Anti-ld  Anti-Id  50  7.9  7.9  8.2 
1,250  2.7  4.1  4.0 
Pre-lgG*  Pre-IgG  10  <1.8  <1.6  <1.8 
* The calculation of the positive (S) to negative (N) ratio was done as previously 
described (19). 
These data represent a composite of four mice that each received two injections 
of pre-IgG. 
The  fact  that  the  anti-Id-induced  anti-HBs  recognized  the  group-specific  a 
determinant of HBsAg lends evidence that anti-Id antibodies can induce protec- 
tive immunity  against  infectious  HBV.  In  this  light,  it  was  demonstrated  that 
antibodies directed against the a determinant confer protection in humans against 
HBV  infection  (32).  No  significant binding  to  the  three  HBsAg  subtypes  was 
obtained with  sera from the four mice that  received two injections of pre-IgG 
alone. 
The theoretical implications  for the use of anti-Id antibodies as vaccines for 
infectious agents  have been previously proposed and  discussed  elsewhere (33- 
35). To our knowledge, the only experimental evidence that anti-Id can induce 
protective immunity against  an  infectious agent has been reported for African 
trypanosomiasis  in  mice (8).  A  second possibility of anti-Id-induced  immunity 
appears  with  HBV.  Previous  studies  (36)  have  demonstrated  that  anti-HBs  is 
responsible for protection against challenge or reinfection with HBV. The fact 
that anti-HBs can be induced by the injection of anti-Id alone and that this anti- 
HBs expresses an idiotypic determinant shared by anti-HBs produced in humans 
naturally infected with HBV suggests the potential for the use of anti-Id vaccines 
for HBV infections. In addition, the anti-HBs also recognized the group-specific 
a determinant of HBsAg, which is the epitope that induces protective immunity 
against HBV. This possibility must await further testing, since only chimpanzees 
and humans  can be infected with human  HBV.  Alternatively, anti-Id could be 
used in conjunction with HBsAg to potentiate the anti-HBs response to a single 
injection  of  HBsAg  by  priming  the  host's  immune  system  before  antigenic 
stimulation. These studies using mice to induce anti-HBs by injection of anti-Id 
represent an  attempt  to  understand  the  humoral  immune  response to  HBsAg 
via modulation of an Id network. It is not known whether the anti-HBs produced KENNEDY AND  DREESMAN  663 
in the modulation process described in this report resulted from the expression 
of clones secreting an Ab-3 (anti-anti-Id antibodies) which expresses the Id and 
binds antigen (33) or represents an internal image (33,  35) of HBsAg in which 
classic antigenic stimulation does not occur. 
Summary 
BALB/c mice receiving antiidiotype antibodies before the injection of hepatitis 
B surface antigen (HBsAg) generated an enhanced anti-HBs response. Mice given 
antiidiotype antibodies in a  soluble form induced predominantly IgM anti-HBs, 
whereas alum-precipitated antiidiotype produced primarily IgG anti-HBs. Injec- 
tion of antiidiotype antibodies alone induced anti-HBs that inhibited a  common 
interspecies anti-HBs  idiotype-antiidiotype reaction and  recognized the group- 
specific determinant  of HBsAg.  These data support the view that  antiidiotype 
antibodies may modulate the immune response to an infectious viral agent. 
Received for publication 29 September  1983. 
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